Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
272lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
16 lessons
9mProtocolsIntermediate
Sermorelin Reconstitution and Dosing: GHRH 1-29 in the Literature
Sermorelin is the short GHRH analog older clinic pages still treat as the gentle GH option. The literature is real. The nightly microgram charts are practice culture, not a modern phase 3 program.
8mSafetyIntermediate
BPC-157 Advisory Review: What It Means for Compounding Access in 2026
BPC-157 is still a research compound, but the advisory review makes one thing clear: access, sourcing, and evidence quality now matter as much as the mechanism.
10mResearchAdvanced
Retatrutide Compounding Quality Control: Why the Debate Matters More Than Hype
Retatrutide may dominate the weight-loss discussion, but the market debate is really about quality control, documentation, and whether a plan can survive real life.
8mSafetyIntermediate
BPC-157's Regulatory Momentum Is Changing How People Read the Evidence
The regulatory story matters because it changes what you can trust, what you should track, and why supply chain quality now sits beside mechanism in the BPC-157 debate.
9mPolicyAdvanced
FDA's July 23 Peptide Panel Backed BPC-157, KPV, and TB-500. Here Is What Happens Next.
The FDA's peptide panel made its first moves on BPC-157, KPV, and TB-500. The vote matters, but the real story is what it changes next and what still has to happen before compounding pharmacies see any relief.
8mResearchAdvanced
FDA Peptide Compounding Review: What the Seven-Peptide Debate Means for Buyers and Clinics
Regulation does not settle the peptide debate by itself. It forces clearer questions about sourcing, safety, evidence, and who is responsible when claims move faster than data.
8mSafetyIntermediate
FDA July 2026 Peptide Review: How to Track BPC-157, TB-500, MOTS-C, Semax, and Epitalon Without the Hype
The July 2026 FDA peptide review is important, but it is not an approval event. Here is how to track the meeting, sourcing changes, and protocol decisions without confusing policy movement with clinical proof.
7mResearchAdvanced
Peptide Regulation and Sourcing Safety in 2026
The biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.
8mPolicyAdvanced
FDA Removes 12 Peptides from Category 2 Restrictions: What Changed in April 2026
The FDA's April 2026 announcement removed 12 peptides from Category 2 restrictions — the biggest regulatory shift in years. BPC-157, TB-500, MOTS-C, GHK-Cu, and Semax are among those affected. Here's what it actually means for your access.
8mResearchAdvanced
FDA Warning Letters Signal a New Era for Peptide Buyers
Seven FDA warning letters in April 2026 show regulators are paying closer attention to online peptide sellers, especially research-use-only marketing that looks like consumer health claims.
9mResearchAdvanced
RFK Jr., the FDA, and BPC-157: What the 2026 Regulatory Reversal Means for Peptide Access
After years of FDA crackdowns on research peptides, a significant regulatory reversal in 2026 has changed the landscape for BPC-157, TB-500, and MOTS-C. Here's what actually happened and what it means for you.
8mStart hereBeginner
503a vs 503b vs Unapproved Peptide Status: What's the Difference?
Confused about peptide compounding categories? This guide breaks down 503a compounding pharmacies, 503b outsourcing facilities, and why “research use only” is not a consumer pathway PeptIQ endorses.
7mPeptidesIntermediate
FDA Removes GHK-Cu from Category 2: What Peptide Users Need to Know
On April 15, 2026, the FDA announced it will remove injectable GHK-Cu from Category 2 — the list that blocked compounding pharmacies from producing it. This is a major regulatory shift for one of the most studied copper peptides in longevity research.
9mPolicyAdvanced
FDA Reclassifies 12 Peptides: What April 2026's Policy Shift Means for Biohackers
The FDA's April 15, 2026 reclassification of 12 research peptides marks the most significant regulatory shift in the space since the 2023 compounding crackdown. Here's a breakdown of the affected compounds, the new compliance landscape, and how to think about your protocol going forward.
10mPolicyAdvanced
FDA Schedules July 2026 Advisory Panel to Reclassify 12 Peptides — What It Means for BPC-157, MOTS-C, and GHK-Cu
An FDA advisory panel scheduled for July 2026 could reshape access to 12 peptides — including BPC-157, MOTS-C, and GHK-Cu. Here's what's on the table, what reclassification would mean in practice, and how to prepare for either outcome.
9mPolicyAdvanced
BPC-157 and the 2026 Regulatory Shift: What the HHS Category 1 Push Means for Peptide Access
After years of regulatory limbo, BPC-157 is at the center of a major policy battle. The RFK Jr.-led HHS push to reclassify it as Category 1 could restore legal compounding access—or the FDA could dig in. Here's where things stand.
Also available at /blog for legacy links.